DÄ internationalArchive21/2020The treatment of heart failure with reduced ejection fraction

cme

The treatment of heart failure with reduced ejection fraction

Dtsch Arztebl Int 2020; 117: 376-85. DOI: 10.3238/arztebl.2020.0376

Berliner, D; Hänselmann, A; Bauersachs, J

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover: Dr. med. Dominik Berliner, Dr. med. Anja Hänselmann, Prof. Dr. med. Johann
Bauersachs
1.Lindenfeld J, Albert NM, Boehmer JP, et al.: HFSA 2010 Comprehensive heart failure practice guideline. J Card Fail 2010; 16: e1–194 CrossRef MEDLINE
2.Ponikowski P, Voors AA, Anker SD, et al.: 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975 CrossRef MEDLINE
3.Mosterd A, Hoes AW: Clinical epidemiology of heart failure. Heart 2007; 93: 1137–46 CrossRef MEDLINE PubMed Central
4.Maggioni AP, Dahlstrom U, Filippatos G, et al.: EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12: 1076–84 CrossRef MEDLINE
5.Seferovic PM, Ponikowski P, Anker SD, et al.: Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21: 1169–86 CrossRef CrossRef
6.Ouwerkerk W, Voors AA, Anker SD, et al.: Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017; 38: 1883–90 CrossRef MEDLINE
7.Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17 CrossRef MEDLINE
8.Zannad F, McMurray JJ, Krum H, et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21 CrossRef MEDLINE
9.Zannad F, Gattis Stough W, Rossignol P, et al.: Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33: 2782–95 CrossRef MEDLINE
10.McMurray JJ, Packer M, Desai AS, et al.: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004 CrossRef MEDLINE
11.Swedberg K, Komajda M, Böhm M, et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875–85 CrossRef CrossRef
12.Tardif JC, O‘Meara E, Komajda M, et al.: Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507–15 CrossRef MEDLINE PubMed Central
13.Bundes­ärzte­kammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale Versorgungs-Leitlinie Chronische Herzinsuffizienz –Langfassung. 3. Auflage. 2019 (last acessed on 31 October 2019).
14.Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33 CrossRef MEDLINE
15.Adams KF, Butler J, Patterson JH, et al.: Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail 2016; 18: 1072–81 CrossRef MEDLINE
16.Hood JWB, Dans AL, Guyatt GH, Jaeschke R, McMurray JJV: Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev 2014; 4: CD002901 CrossRef MEDLINE PubMed Central
17.Bavendiek U, Berliner D, Davila LA, et al.: Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur J Heart Fail 2019; 21: 676–84 CrossRef MEDLINE PubMed Central
18.Jankowska EA, Rozentryt P, Witkowska A, et al.: Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872–80 CrossRef MEDLINE
19.Anker SD, Comin Colet J, Filippatos G, et al.: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436–48 CrossRef MEDLINE
20.Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.: Beneficial effects of long-term intra-venous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657–68 CrossRef MEDLINE PubMed Central
21.McMurray JJV, Solomon SD, Inzucchi SE, et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995–08 CrossRef MEDLINE
22.Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.: 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793–867 CrossRef MEDLINE
23.Kober L, Thune JJ, Nielsen JC, et al.: Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375: 1221–30 CrossRef MEDLINE
24.Elming MB, Nielsen JC, Haarbo J, et al.: Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 2017; 136: 1772–80 CrossRef MEDLINE
25.Duncker D, Veltmann C: Role of the wearable defibrillator in newly diagnosed heart failure. Curr Heart fail Rep 2018; 15: 368–75 CrossRef MEDLINE PubMed Central
26.Abraham WT, Fisher WG, Smith AL, et al.: Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845–53 CrossRef MEDLINE
27.Moss AJ, Hall WJ, Cannom DS, et al.: Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329–38 CrossRef MEDLINE
28.Tang AS, Wells GA, Talajic M, et al.: Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385–95 CrossRef MEDLINE
29.Cleland JG, Daubert JC, Erdmann E, et al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–49 CrossRef MEDLINE
30.Bristow MR, Saxon LA, Boehmer J, et al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–50 CrossRef MEDLINE
31.Hayes DL, Boehmer JP, Day JD, et al.: Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart rhythm 2011; 8: 1469–75 CrossRef MEDLINE
32.Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF: Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 2002; 144: 524–9 CrossRef MEDLINE
33.Obadia J-F, Messika-Zeitoun D, Leurent G, et al.: Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018; 379: 2297–306 CrossRef MEDLINE
34.Stone GW, Lindenfeld J, Abraham WT, et al.: Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379: 2307–18 CrossRef MEDLINE
35.Arnold SV, Chinnakondepalli KM, Spertus JA, et al.: Health status after transcatheter mitral-valve repair in heart failure and secondary mitral regurgitation. COAPT Trial 2019; 73: 2123–32 CrossRef MEDLINE PubMed Central
36.Grayburn PA, Sannino A, Packer M: Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and CO-APT trials. JACC Cardiovasc Imaging 2019; 12: 353–62 CrossRef MEDLINE
37.Ertl G, Angermann CE, Bekeredjian R, et al.: Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF NETs) und Herzinsuffizienz-Einheiten („Heart Failure Units“, HFUs) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz. Der Kardiologe 2016; 10: 222–35 CrossRef
38.Yancy CW, Jessup M, Bozkurt B, et al.: 2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J AM Coll Cardiol. 2013; 62: e147–e239 CrossRef MEDLINE
39.Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J: Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017; 38: 2095–9 CrossRef MEDLINE PubMed Central
40.Bavendiek U, Aguirre Davila L, Schwab J, et al.: P6168Digitoxin serum concentrations affecting patient safety and potential outcome in patients with HFrEF–analyses of the ongoing DIGIT-HF-trial. Eur Heart J 2017; 38 MEDLINE MEDLINE
e1.Benjamin EJ, Blaha MJ, Chiuve SE, et al.: Heart Disease and Stroke Statistics-2017 Update: A report from the American Heart Association. Circulation 2017; 135: e146–e603 CrossRef
e2.Ferrari R, Ceconi C, Tavazzi L, Ghio S, Boffa G, Fucili A: Heart failure: 150 questions & answers. 2nd ed. Neuilly-sur-Seine Cedex: Servier; 2011.
e3.Gheorghiade M, Bohm M, Greene SJ, et al.: Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125–35 CrossRef MEDLINE
e4.McMurray JJ, Krum H, Abraham WT, et al.: Aliskiren, Enalapril, or Aliskiren and Enalapril in heart failure. N Engl J Med 2016; 374: 1521–32 CrossRef MEDLINE
e5.D‘Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M: Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 2017; 19: 710–7 CrossRef MEDLINE
e6.Lewis EF, Claggett BL, McMurray JJV, et al.: Health-related quality of life outcomes in PAR-ADIGM-HF. Circ Heart Fail 2017; 10 CrossRef
e7.de Diego C, Gonzalez-Torres L, Nunez JM, et al.: Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart rhythm 2018; 15: 395–402 CrossRef MEDLINE
e8.Januzzi JL, Jr, Prescott MF, Butler J, et al.: Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-Valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019; 322: 1085–95 CrossRef MEDLINE PubMed Central
e9.Böhm M, Swedberg K, Komajda M, et al.: Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886–94 CrossRef
e10.Ekman I, Chassany O, Komajda M, et al.: Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011; 32: 2395–404 CrossRef MEDLINE
e11.Armstrong PW, Pieske B, Anstrom KJ et al.: Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020 [epub ahead of print] CrossRef MEDLINE
e12.Cazeau S, Leclercq C, Lavergne T, et al.: Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873–80 CrossRef MEDLINE
e13.Auricchio A, Stellbrink C, Sack S, et al.: Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026–33 CrossRef CrossRef
e14.Gervais R, Leclercq C, Shankar A, et al.: Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail 2009; 11: 699–705 CrossRef MEDLINE
e15.Zareba W, Klein H, Cygankiewicz I, et al.: Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation 2011; 123: 1061–72 CrossRef MEDLINE
e16.Sundaram V, Sahadevan J, Waldo AL, et al.: Implantable cardioverter-defibrillators with versus without resynchronization therapy in patients with a QRS duration > 180 ms. J Am Coll Cardiol 2017; 69: 2026–36 CrossRef MEDLINE PubMed Central
e17.Ruschitzka F, Abraham WT, Singh JP, et al.: Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395–405 CrossRef MEDLINE
e18.Shenkman HJ, Pampati V, Khandelwal AK, et al.: Congestive heart failure and QRS duration: establishing prognosis study. CHEST 2002; 122: 528–34 CrossRef MEDLINE
e19.Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al.: Vagus nerve stimulation for the treatment of heart failure: the INOVATE-HF trial. J Am Coll Cardiol 2016; 68: 149–58 CrossRef MEDLINE
e20.Baumgartner H, Falk V, Bax JJ, et al.: 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739–91 CrossRef MEDLINE
e21.Bursi F, Barbieri A, Grigioni F, et al.: Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail 2010; 12: 382–8 CrossRef MEDLINE
e22.Pfister R, Hausleiter J, Boekstegers P, et al.: Role of percutaneous edge-to-edge repair in secondary mitral regurgitation after MITRA-FR and COAPT : a comment by the section of AV-valve treatment of the Working Group of Interventional Cardiology (AGIK) of the German Society of Cardiology (DGK). Clin Res Cardiol 2019; 108: 969−73 CrossRef MEDLINE
e23.Chioncel O, Lainscak M, Seferovic PM, et al.: Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574–85 CrossRef MEDLINE
e24.Fox K, Komajda M, Ford I, et al.: Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34: 2263–70 CrossRef MEDLINE
e25.Komajda M, Böhm M, Borer JS, et al.: Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 2018; 20: 1315–22 CrossRef MEDLINE
e26.Srivastava PK, Claggett BL, Solomon SD, et al.: Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with Angiotensin Receptor-Neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: An analysis of data from the PARADIGM-HF trial. JAMA Cardiology 2018; 3: 1226–31 CrossRef MEDLINE PubMed Central
e27.Duncker D, Veltmann C: Device therapy in heart failure with reduced ejection fraction—cardiac resynchronization therapy and more. Herz 2018; 43: 415–22 CrossRef MEDLINE